AQR Capital Management
BLCM

AQR Capital Management’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

AQR Capital Management’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,666
Closed -$192K – 2289
2017
Q3 		$192K Buy
+1,666
New +$175K ﹤0.01% 2173

Other funds holding BLCM

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AQR Capital Management's BLCM Position: Q4 2017 in Review

AQR Capital Management sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q4 2017, closing a stake of 1,666 shares — an estimated $192K sold.

AQR Capital Management first reported a position in BLCM in Q3 2017 and held it in 1 quarter. The position peaked at $192K in Q3 2017. 91 funds tracked by Wall St. Rank hold BLCM as of Q4 2017.

  • AQR Capital Management reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
  • AQR Capital Management sold 1,666 Bellicum Pharmaceuticals, Inc. shares in Q4 2017, an estimated $192K.
  • AQR Capital Management first reported a position in Bellicum Pharmaceuticals, Inc. in Q3 2017 and held it in 1 quarter.
  • AQR Capital Management's Bellicum Pharmaceuticals, Inc. position peaked at $192K in Q3 2017.
  • 91 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q4 2017.

Based on AQR Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.